US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time

FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.